Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577887 | 0.96 | OPRM1 (0.51) | GLSSMN1; SMN2LMNAPRKAA2MAPT | |
| SCHEMBL5577638 | 0.85 | CXCR3 (0.50) | SMN1; SMN2PRKAA2CXCR3 | |
| SCHEMBL5577938 | 0.85 | CXCR3 (0.44) | SMN1; SMN2MAPTCXCR3L3MBTL1 | |
| SCHEMBL5577797 | 0.85 | GAA (0.49) | SMN1; SMN2LMNAMAPTMCHR1L3MBTL1 | |
| SCHEMBL5577544 | 0.83 | CXCR3 (0.46) | PRKAA2CXCR3MCHR1 | |
| SCHEMBL5577825 | 0.82 | PRKAA2 (0.44) | PRKAA2CXCR3MCHR1OPRM1NPC1 | |
| SCHEMBL5577473 | 0.82 | ALDH1A1 (0.51) | SMN1; SMN2LMNAMAPTMCHR1L3MBTL1 | |
| SCHEMBL5577474 | 0.82 | MT-CO2 (0.46) | GLSSMN1; SMN2LMNAPRKAA2 | |
| SCHEMBL5577923 | 0.80 | HTR2C (0.46) | CXCR3MCHR1 | |
| SCHEMBL5577660 | 0.80 | CXCR3 (0.48) | PRKAA2MAPTCXCR3MCHR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | GLS 122/4885SMN1; SMN2 2012/4885LMNA 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.